For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
May 13, 2022
- Health Minister Vows Thorough Discussions on Drug Pricing, Mentions Policy Veterans’ Proposals
May 13, 2022
- MHLW Panel Clears Solasia’s PTCL Drug for Approval
May 13, 2022
- Japan Confirms 1st Cases of BA.4, BA.5 Omicron Subvariants
May 13, 2022
- Japan Enacts Economic Security Law; Supply Chain Clauses to Take Effect in 9 Months after Promulgation
May 12, 2022
- Side Effects after Drug Switches Up for MHLW Panel Review: Minister
May 11, 2022
- Xevudy’s Reduced Efficacy against BA.2 Cited in Updated COVID Guide
May 11, 2022
- PMDA Publishes 1st Example of GMP Shortfalls; Failure to Check Name of Raw Material Supplier
May 10, 2022
- Solasia’s PTCL Med, Rinvoq and Adcetris Label Expansions Up for PAFSC Review on May 12
May 9, 2022
- Maruho’s Rozex in Line for Rosacea Nod in Japan
May 9, 2022
- Probable Cases of Mysterious Pediatric Hepatitis Now Increased to 7 in Japan
May 9, 2022
- Japan Panel OKs Second Booster for Age 60-Plus, and High-Risk Adults
April 28, 2022
- Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
April 28, 2022
- Products Filed for Conditional OK Can Be Switched to Emergency Approval: MHLW Official
April 27, 2022
- Japan Panel OKs Comirnaty, Spikevax for 4th Shot, Use Limited to High-Risk People
April 26, 2022
- SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
- MHLW to Further Bankroll Shionogi’s COVID-19 Pill, Kowa’s Ivermectin
April 25, 2022
- Japan to Raise Pharmacy Stock Levels for Lagevrio, Paxlovid
April 25, 2022
- Upper House Starts Deliberations on PMD Law Amendment Bill
April 25, 2022
- Single-Year Comparison of PMP and Deferred Price Cuts Not Appropriate: Health Minister
April 22, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…